Brevan Howard Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Brevan Howard Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-27,056	Closed	-$631K	–	2208
2025 Q4	$631K	Buy	27,056 +5,991	+28%	+$133K	0.01%	984
2025 Q3	$415K	Buy	21,065 +2,889	+16%	+$59.4K	﹤0.01%	1389
2025 Q2	$394K	Buy	+18,176	New	+$429K	﹤0.01%	1450
2025 Q1	–	Sell	-12,817	Closed	-$267K	–	1205
2024 Q4	$267K	Sell	12,817 -7,252	-36%	-$156K	﹤0.01%	817
2024 Q3	$399K	Sell	20,069 -9,739	-33%	-$181K	﹤0.01%	755
2024 Q2	$462K	Buy	+29,808	New	+$464K	﹤0.01%	638
2024 Q1	–	Sell	-32,992	Closed	-$555K	–	1057
2023 Q4	$555K	Buy	+32,992	New	+$451K	0.01%	437

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Brevan Howard Capital Management's CPRX Position: Q1 2026 in Review

Brevan Howard Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q1 2026, closing a stake of 27,056 shares — an estimated $631K sold.

Brevan Howard Capital Management first reported a position in CPRX in Q4 2023 and held it in 7 quarters. The position peaked at $631K in Q4 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Brevan Howard Capital Management reported no remaining Catalyst Pharmaceutical position as of Q1 2026 after selling out during the quarter.
Brevan Howard Capital Management sold 27,056 Catalyst Pharmaceutical shares in Q1 2026, an estimated $631K.
Brevan Howard Capital Management first reported a position in Catalyst Pharmaceutical in Q4 2023 and held it in 7 quarters.
Brevan Howard Capital Management's Catalyst Pharmaceutical position peaked at $631K in Q4 2025.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.